Verdence Capital Advisors’s Processa Pharmaceuticals PCSA Stock Holding History

Verdence Capital Advisors’s Portfolio PCSA Stock Details PCSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-40	Closed	-$9.96K	–	573
2023 Q2	$9.96K	Sell	40 -10	-20%	-$2.95K	﹤0.01%	532
2023 Q1	$12.5K	Sell	50 -70	-58%	-$28.2K	﹤0.01%	535
2022 Q4	$65.9K	Hold	120	–	–	0.01%	488
2022 Q3	$135K	Hold	120	–	–	0.02%	500
2022 Q2	$168K	Hold	120	–	–	0.02%	496
2022 Q1	$180K	Sell	120 -6	-5%	-$11.4K	0.02%	497
2021 Q4	$310K	Sell	126 -22	-15%	-$68.2K	0.04%	409
2021 Q3	$632K	Buy	+148	New	+$506K	0.08%	235

Other funds holding PCSA

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CBA

Coastal Bridge Advisors Westport, Connecticut $1.41B AUM 24.15% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

MCP

Mirador Capital Partners Pleasanton, California $817M AUM 42.46% 1-Year Est. Return

Verdence Capital Advisors's PCSA Position: Q3 2023 in Review

Verdence Capital Advisors sold out of Processa Pharmaceuticals (PCSA) in Q3 2023, closing a stake of 40 shares — an estimated $9.96K sold.

Verdence Capital Advisors first reported a position in PCSA in Q3 2021 and held it in 8 quarters. The position peaked at $632K in Q3 2021. 18 funds tracked by Wall St. Rank hold PCSA as of Q3 2023.

Verdence Capital Advisors reported no remaining Processa Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Verdence Capital Advisors sold 40 Processa Pharmaceuticals shares in Q3 2023, an estimated $9.96K.
Verdence Capital Advisors first reported a position in Processa Pharmaceuticals in Q3 2021 and held it in 8 quarters.
Verdence Capital Advisors's Processa Pharmaceuticals position peaked at $632K in Q3 2021.
18 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q3 2023.

Based on Verdence Capital Advisors's 13F filing for Q3 2023, filed 25 Oct 2023.